{"id":37462,"date":"2025-07-16T17:44:51","date_gmt":"2025-07-16T09:44:51","guid":{"rendered":"https:\/\/flcube.com\/?p=37462"},"modified":"2025-07-16T17:44:52","modified_gmt":"2025-07-16T09:44:52","slug":"tcelltech-secures-usd-40-million-series-b-funding-for-tx-103-car-t-therapy-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37462","title":{"rendered":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development"},"content":{"rendered":"\n<p>China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company&#8217;s core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&amp;D of other pipeline projects, global team expansion, and the acceleration of the company&#8217;s international strategic layout and business development (BD) collaborations.<\/p>\n\n\n\n<p><strong>TX-103: B7-H3-Targeted CAR-T Therapy<\/strong><br>TX-103, a B7-H3-targeted CAR-T cell therapy, has entered global regulatory clinical studies for solid tumors, including recurrent glioblastoma (rGBM). In early-stage clinical trials, TX-103 demonstrated outstanding efficacy and safety. The therapy significantly prolonged median overall survival (mOS) and improved one-year survival rates in rGBM patients, showcasing a favorable tolerability profile.<\/p>\n\n\n\n<p><strong>Clinical Progress and Future Outlook<\/strong><br>The positive results from early-stage trials highlight TX-103&#8217;s potential to address significant unmet medical needs in oncology. As Tcelltech advances its clinical development and international expansion, the company aims to establish a strong presence in the global immunotherapy market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37463,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,1612],"class_list":["post-37462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-tcelltech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company&#039;s core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&amp;D of other pipeline projects, global team expansion, and the acceleration of the company&#039;s international strategic layout and business development (BD) collaborations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37462\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development\" \/>\n<meta property=\"og:description\" content=\"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company&#039;s core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&amp;D of other pipeline projects, global team expansion, and the acceleration of the company&#039;s international strategic layout and business development (BD) collaborations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37462\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T09:44:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-16T09:44:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development\",\"datePublished\":\"2025-07-16T09:44:51+00:00\",\"dateModified\":\"2025-07-16T09:44:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1612.webp\",\"keywords\":[\"Finance\",\"Tcelltech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37462#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37462\",\"name\":\"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1612.webp\",\"datePublished\":\"2025-07-16T09:44:51+00:00\",\"dateModified\":\"2025-07-16T09:44:52+00:00\",\"description\":\"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company's core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company's international strategic layout and business development (BD) collaborations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37462\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1612.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1612.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37462#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company's core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company's international strategic layout and business development (BD) collaborations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37462","og_locale":"en_US","og_type":"article","og_title":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development","og_description":"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company's core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company's international strategic layout and business development (BD) collaborations.","og_url":"https:\/\/flcube.com\/?p=37462","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-16T09:44:51+00:00","article_modified_time":"2025-07-16T09:44:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37462#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37462"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development","datePublished":"2025-07-16T09:44:51+00:00","dateModified":"2025-07-16T09:44:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37462"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","keywords":["Finance","Tcelltech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37462#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37462","url":"https:\/\/flcube.com\/?p=37462","name":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37462#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","datePublished":"2025-07-16T09:44:51+00:00","dateModified":"2025-07-16T09:44:52+00:00","description":"China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company's core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company's international strategic layout and business development (BD) collaborations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37462#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37462"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37462#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","width":1080,"height":608,"caption":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37462#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1612.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37462"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37462\/revisions"}],"predecessor-version":[{"id":37464,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37462\/revisions\/37464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37463"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}